Why KDP, DXCM, and MRNA Shares are On Sale
On Monday, Keurig Dr Pepper (KDP) announced that it would spend $18 billion to buy a Dutch coffee giant. KDP shares cratered, falling by 11.48% to close at $31.10. The stock is now trading at prices not seen since February.
KDP will acquire JDE Peet’s (JDEPF), offering an all-cash transaction. JDEPF shares jumped by 24.79%, a high not seen in three years. The acquisition will achieve nearly $400 million in cost savings over three years. It will add to earnings in the first year that the deal closes.
To raise cash levels, Keurig will split its coffee and beverage units into two separate entities.
Dexcom (DXCM) dropped by 7.66% on Monday to close at $75.96. Watch for shares rebounding back toward $80 next. The company did not post any news. Its Q2 results, released last month, set off a downtrend. Share interest is only 2.16%, so the negative momentum on DXCM is not clear.
Moderna (MRNA) continued to suffer from another setback. The Daily Beast reported that the Trump administration might ban the COVID-19 vaccine “within months.” If this is true, this is a significant setback for healthcare, science, and the prevention of disease. The U.S. already invested in developing vaccines during the 2020 pandemic. People should decide if they want the jap. Health agencies should advise on any vaccine based on clinical data.
MRNA stock closed at $25.35, down by 6.53%.
